14-Nov-2024 6:00 AM CST - Business Wire bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate, said Andrew Obenshain, chief executive officer. This momentum, coupled with steps
6-Nov-2024 3:15 PM CST - Business Wire bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced that it partially adjourned its annual meeting of stockholders (Annual Meeting) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the proxy statement). The C
24-Sep-2024 6:00 AM CST - Business Wire bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Companys cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reductio
14-Nov-2024 6:00 AM CST - Business Wire bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate, said Andrew Obenshain, chief executive officer. This momentum, coupled with steps
6-Nov-2024 3:15 PM CST - Business Wire bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced that it partially adjourned its annual meeting of stockholders (Annual Meeting) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the proxy statement). The C
24-Sep-2024 6:00 AM CST - Business Wire bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Companys cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reductio
